Han Y, Randell E, Vasdev S, Gill V, Gadag V, Newhook LA, et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with type 1 diabetes. Mol Cell Biochem 2007;305:123–31. [Web of Science]
Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, et al. Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction. J Biol Chem 1994;269:20275–80.
Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999;344:109–16.
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1–9.
Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 1999;256:89–93.
Lu J, Randell E, Han Y, Adeli K, Krahn J, Meng QH. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin Biochem 2011;44:307–11. [Web of Science]
Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. Hypertension 2010;56:471–6. [Web of Science]
Nakayama K, Nakayama M, Iwabuchi M, Terawaki H, Sato T, Kohno M, et al. Plasma α-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am J Nephrol 2008;28:871–8. [Web of Science]
Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving H-H, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011;34:442–7. [Web of Science]
Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, et al. Advanced glycation end products and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 2011;32:763–77. [Web of Science]
McLellan AC, Phillips SA, Thornalley PJ. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. Anal Biochem 1992;206:17–23.
Mittelmaier S, Funfrocken M, Fenn D, Fichert T, Pischetsrieder M. Identification and quantification of the glucose degradation product glucosone in peritoneal dialysis fluids by HPLC/DAD/MSMS. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:877–82.
Nemet I, Varga-Defterdarovic L, Turk Z. Preparation and quantification of methylglyoxal in human plasma using reverse-phase high-performance liquid chromatography. Clin Biochem 2004;37:875–81.
Neng NR, Cordeiro CA, Freire AP, Nogueira JM. Determination of glyoxal and methylglyoxal in environmental and biological matrices by stir bar sorptive extraction with in-situ derivatization. J Chromatogr A 2007;1169:47–52.
Dhar A, Desai K, Liu J, Wu L. Methylglyoxal, protein binding and biological samples: are we getting the true measure? J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1093–100.
Mittelmaier S, Funfrocken M, Fenn D, Berlich R, Pischetsrieder M. Quantification of the six major α-dicarbonyl contaminants in peritoneal dialysis fluids by UHPLC/DAD/MSMS. Anal Bioanal Chem 2011;401:1183–93. [Web of Science]
Randell EW, Vasdev S, Gill V. Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J Pharmacol Toxicol Methods 2005;51:153–7.
Kampf CJ, Bonn B, Hoffmann T. Development and validation of a selective HPLC-ESI-MS/MS method for the quantification of glyoxal and methylglyoxal in atmospheric aerosols (PM2.5). Anal Bioanal Chem 2011;401:3115–24. [Web of Science]
Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437–44. [Web of Science]
Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198–202.
Fleming T, Cuny J, Nawroth G, Djuric Z, Humpert PM, Zeier M, et al. Is diabetes an acquired disorder of reactive glucose metabolites and their intermediates? Diabetologia 2012;55:1151–5. [Web of Science]
Mikesh LM, Bruns DE. Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin Chem 2008;54:930–2. [Web of Science]
Ohmori S, Mori M, Shiraha K, Kawase M. Biosynthesis and degradation of methylglyoxal in animals. Prog Clin Biol Res 1989;290:397–412.